Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net loss	$ (18,153)	$ (10,104)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,358	1,151
Inventory step-up amortization		164
Credit loss expense on accounts receivable	(171)	20
Reduction in the carrying amount of right-of-use assets	348	128
Stock-based compensation expense	3,827	3,386
Non-cash interest expense		22
Changes in operating assets and liabilities:
Accounts receivable	1,319	2,227
Prepaid expenses and other assets	(2,070)	(1,744)
Inventory	(484)	(2,327)
Other non-current assets	1	(16)
Accounts payable	(5,306)	(2,109)
Accrued compensation and benefits, other accrued expenses and other current liabilities	(4,921)	(5,598)
Contract acquisition costs	(41)	(72)
Operating lease liabilities	(87)	(307)
Other non-current liabilities	(271)	(107)
Deferred revenue	2,956	1,197
Net cash used in operating activities	(21,695)	(14,089)
Investing activities
Purchases of property and equipment	(1,394)	(79)
Proceeds from RADx grant on assets purchased	520	2,514
Net cash (used in) provided by investing activities	(874)	2,435
Financing activities
Proceeds from stock options exercised	385	3,076
Sale of common stock in underwritten public offering, net		269,718
Proceeds from ESPP purchase	594	519
Net cash provided by financing activities	979	273,313
Net (decrease) increase in cash and cash equivalents	(21,590)	261,659
Effect of foreign currency exchange rate on cash	(558)	(171)
Cash, restricted cash, and cash equivalents at beginning of period	399,042	182,584
Cash, restricted cash, and cash equivalents at end of period	376,894	$ 444,072
Noncash transactions:
Right-of-use asset obtained in exchange for lease liabilities	$ 18,156